Evidence map›Paper›PMID 42382101›Full record

ArticleeNeurologicalSci2026

The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.

Courtney E Stewart, Kaci P French, Traver J Wright, Kayla Wilhoit, Kathleen M Randolph, Christopher P Danesi, Charles R Gilkison, Christof Karmonik, Lei Lu, Edgar L Dillon and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eNeurologicalSci, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02553603 (The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02553603 phase1completednot on this map

The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

TypeinterventionalSponsorThe University of Texas Medical Branch, GalvestonRan2017 to 2019Enrolled22ConditionsMild Cognitive ImpairmentArmsGrowth Hormone Releasing Hormone (GHRH), Placebo Growth Hormone Releasing Hormone
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Courtney E StewartIndependent Researcher, East Liverpool, OH 43920, USA.
Kaci P FrenchSchool of Medicine, The University of Texas Medical Branch, Galveston, TX 77555, USA.
Traver J WrightDepartment of Internal Medicine, The University of Texas Medical Branch, Galveston, TX 77555, USA.
Kayla WilhoitTranslational Imaging Center, Houston Methodist Research Institute, Houston, TX 77030, USA.
Kathleen M RandolphDepartment of Internal Medicine, The University of Texas Medical Branch, Galveston, TX 77555, USA.
Christopher P DanesiDepartment of Internal Medicine, The University of Texas Medical Branch, Galveston, TX 77555, USA.
Charles R GilkisonDepartment of Internal Medicine, The University of Texas Medical Branch, Galveston, TX 77555, USA.
Christof KarmonikTranslational Imaging Center, Houston Methodist Research Institute, Houston, TX 77030, USA.
Lei LuDepartment of Neurology, The University of Texas Medical Branch, Galveston, TX 77555, USA.
Edgar L DillonDepartment of Internal Medicine, The University of Texas Medical Branch, Galveston, TX 77555, USA.
William J DurhamDepartment of Internal Medicine, The University of Texas Medical Branch, Galveston, TX 77555, USA.
Randall J UrbanDepartment of Internal Medicine, The University of Texas Medical Branch, Galveston, TX 77555, USA.
Melinda Sheffield-MooreDepartment of Internal Medicine, The University of Texas Medical Branch, Galveston, TX 77555, USA.
Brent E MaselDepartment of Neurology, The University of Texas Medical Branch, Galveston, TX 77555, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cognitive decline with age and other clinical conditions are linked with reduced hypothalamic-pituitary-adrenal (HPA) axis function. Stimulating the HPA axis with supplemental growth hormone (GH) treatment can improve cognition, however, potential direct effects of stimulation with growth hormone releasing hormone (GHRH) are not established. In a double-blind, placebo-controlled pilot trial, we assessed 22 subjects with baseline cognition ranging from normal cognition to mild cognitive impairment before and after 10 weeks of treatment with low-dose tesamorelin (1 mg; GHRH analog) or placebo. We compared groupwise changes in body composition, fatigue, sleep, physical performance, glucose tolerance, cognitive function, and brain morphometry and functional connectivity. Low-dose GHRH treatment was not directly linked with significant changes in study measures. Using advanced machine learning (ML) models to further examine the data we identified potential treatment-related differences in areas of the brain related to cognitive function including the right anterior cingulate and left superior frontal occipital fasciculus. This pilot study highlights the potential benefits of pairing cognitive tests and neuroimaging with ML tools to achieve greater sensitivity for treatment-related effects. The clinical trial registration number is: NCT02553603.

Indexed as

Brain connectivityBrain morphometryCognitive biomarkersCognitive performanceGrowth hormone-releasing hormoneMachine learning analysis

Identifiers

PMID42382101
PMCPMC13316082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.